Study S003398

A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Oral Single Doses of NNC0113-6856 in Healthy Male Participants

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05521256
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 70
Start: 2022-08-26
Primary completion: 2023-03-27
Lead sponsor: Novo Nordisk A/S
Conditions: Healthy Volunteers; Type 2 Diabetes
Interventions: DRUG:NNC0113-6856; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1270-0813; EUDRACT_NUMBER:2021-005397-26

Registered primary outcomes

Number of adverse events [From time of dosing (day 1) until completion of the follow-up visit (Day 42)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.